Part A—Drugs and Devices (§§ 351—360n)
- § 351. Adulterated drugs and devices
- § 352. Misbranded drugs and devices
- § 353. Exemptions and consideration for certain drugs, devices, and biological products
- § 353a. Pharmacy compounding
- § 353b. Prereview of television advertisements
- § 354. Veterinary feed directive drugs
- § 355. New drugs
- § 355-1. Risk evaluation and mitigation strategies
- § 355a. Pediatric studies of drugs
- § 355b. Adverse-event reporting
- § 355c. Research into pediatric uses for drugs and biological products
- § 355d. Internal committee for review of pediatric plans, assessments, deferrals, and waivers
- § 355e. Pharmaceutical security
- § 356. Fast track products
- § 356-1. Accelerated approval of priority countermeasures
- § 356a. Manufacturing changes
- § 356b. Reports of postmarketing studies
- § 356c. Discontinuance of life saving product
- § 357. Repealed.]
- § 358. Authority to designate official names
- § 359. Nonapplicability of subchapter to cosmetics
- § 360. Registration of producers of drugs or devices
- § 360a. Clinical trial guidance for antibiotic drugs
- § 360b. New animal drugs
- § 360c. Classification of devices intended for human use
- § 360d. Performance standards
- § 360e. Premarket approval
- § 360e-1. Pediatric uses of devices
- § 360f. Banned devices
- § 360g. Judicial review
- § 360h. Notification and other remedies
- § 360i. Records and reports on devices
- § 360j. General provisions respecting control of devices intended for human use
- § 360k. State and local requirements respecting devices
- § 360l. Postmarket surveillance
- § 360m. Accredited persons
- § 360n. Priority review to encourage treatments for tropical diseases